Bank of America Securities Keeps Their Buy Rating on Xenon (XENE)
Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Xenon on March 9 and set a price target of $77.00. The company’s shares closed yesterday at $62.76.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Gerberry covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Eli Lilly & Co, and Bristol-Myers Squibb. According to TipRanks, Gerberry has an average return of 16.6% and a 61.73% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xenon with a $75.88 average price target, a 20.91% upside from current levels. In a report released on March 10, Deutsche Bank also maintained a Buy rating on the stock with a $90.00 price target.
Based on Xenon’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $105.26 million. In comparison, last year the company had a GAAP net loss of $65.69 million
Read More on XENE:
Disclaimer & DisclosureReport an Issue
- Xenon Strengthens Balance Sheet With Major Equity Offering
- Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
- Xenon Raises $650 Million in Upsized U.S. Equity Offering
- Xenon Pharmaceuticals: Buy Rating Backed by Superior X-TOLE2 Phase 3 Results and Commercial Upside for Azetukalner in Focal Epilepsy
- Xenon Pharmaceuticals price target raised to $64 from $47 at Wedbush
